对铁亡相关基因的多重转录组学分析揭示了CAFs外体COX4I2作为骨髓瘤中新的治疗点
Xiaoying Niu1, Xinxin Zhang2, Zhongyi Li3
1Bone and Soft Tissue Department, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China.
Frontiers in cell and developmental biology
|September 22, 2025
概括
骨髓瘤细胞通过癌症相关纤维细胞的异位COX4I2转移抵御铁. 这种机制促进瘤生长,并建议外体COX4I2作为骨髓瘤的治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 骨髓瘤是一种流行的儿科癌症,复发率很高.
- 铁灭,一种受调节的细胞死亡形式,为癌症提供了潜在的治疗策略.
- 铁死在骨髓瘤中的预后作用和调节机制尚不清楚.
研究的目的:
- 根据与铁亡相关的基因开发骨肉瘤的预后模型.
- 为了确定关键的调节基因参与铁死在骨髓瘤微环境.
- 研究特定蛋白质的外体转移在调节铁亡和瘤进展中的作用.
主要方法:
- 使用LASSO回归和独立队列构建和验证一个12基因铁灭预后模型.
- 通过机器学习算法和单细胞RNA测序识别枢纽基因.
- 通过先进的显微镜和生化分析,评估从癌症相关纤维细胞 (CAF) 到骨髓瘤细胞的外体COX4I2转移.
主要成果:
- 基于铁亡的风险模型显示出显著的预后能力.
- 鉴定出COX4I2是一种主要在CAF中表达的 stromal中心基因.
- 外体COX4I2转移抑制了铁,增强了骨髓瘤细胞的扩散,并在体内促进了瘤的生长.
结论:
- 外体COX4I2在抑制铁亡和驱动骨髓瘤进展方面发挥着至关重要的作用.
- COX4I2 是一个潜在的诊断生物标志物和骨髓瘤的治疗点.
- 向外体COX4I2可能为基于铁亡的癌症干预提供一种新的策略.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K


